The QTDP program was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.
NovaBay is a clinical stage biotechnology company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells.